TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3044068
Drug: High sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High sucrose diet (220 g of sucrose daily)
Study: 3044068
Drug: Complex carbohydrate
Normalized name: Complex carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex carbohydrate (CHO) diet (less than 3 g of sucrose daily)
Study: 3044068
Drug: High sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High sucrose diet (220 g of sucrose daily) in patients with preexisting higher triglyceridemia
Study: 24341382
Drug: AZD8309 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8309 (300 mg)
Study: 21495995
Drug: Oral lymecycline
Normalized name: lymecycline
DrugBank: Lymecycline (DB00256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lymecycline 300 mg with adapalene 0.1%-BPO 2.5% (A/BPO)
Study: 21495995
Drug: Oral lymecycline
Normalized name: lymecycline
DrugBank: Lymecycline (DB00256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lymecycline 300 mg with vehicle gel
Study: 30121072
Drug: Intraoperative GDFT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative GDFT guided by PVI, administering fluid boluses of 3 ml/kg tetrastarch aiming at a PVI value below 10%.
Study: 25722222
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin therapy with glargine
Study: 25722222
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin therapy with detemir
Study: 19828484
Drug: Normal magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal magnesium levels (<=1.0 mmol/l)
Study: 17984189
Drug: Glutamine (Gln)
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine (Gln) supplementation (100 mg kg(‐1) body weight)
Study: 17984189
Drug: Alanine (Ala)
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alanine (Ala) supplementation (100 mg kg(‐1) body weight)
Study: 1514487
Drug: Single-port infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-port infusion protocol
Study: 6487499
Drug: Enprofylline at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline at plasma concentrations of 4.0 micrograms/ml
Study: 6487499
Drug: Theophylline at
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline at plasma concentrations of 5.5 micrograms/ml
Study: 6487499
Drug: Theophylline at
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline at plasma concentrations of 10.8 micrograms/ml
Study: 6487499
Drug: Theophylline at
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline at plasma concentrations of 15.2 micrograms/ml
Study: 6487499
Drug: Enprofylline (above
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline (above 2.9 micrograms/ml)
Study: 6487499
Drug: Theophylline infusion
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline infusion
Study: 29244746
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (70 mL, 5.6 mmol NO₃‐)
Study: 19364250
Drug: Subcutaneous apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous apomorphine co-administered with trimethobenzamide or domperidone premedication
Study: 15024927
Drug: Unsupervised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised treatment with primaquine (14 doses provided upon enrollment)
Study: 15960211
Drug: Diclofenac intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac intramuscular single dose
Study: 15960211
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received morphine by Patient Controlled Analgesia (PCA)
Study: 8739682
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol solution given twice daily
Study: 8739682
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol in gel‐forming solution given once daily
Study: 8739682
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol solution
Study: 8739682
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol in gel‐forming solution
Study: 1890650
Drug: B2 agonists
Normalized name: VITAMIN B2
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: B2 agonists kallidin
Study: 1890650
Drug: B2 agonists
Normalized name: VITAMIN B2
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: B2 agonists bradykinin
Study: 22162258
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa oil capsules 500 mg twice/day
Study: 22162258
Drug: Placebo (starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch filled capsules)
Study: 12127708
Drug: Cefaclor (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (40 mg/kg/day in two doses for 5 days)
Study: 12127708
Drug: Amoxycillin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (40 mg/kg/day in three doses for 10 days)
Study: 21863679
Drug: Manually controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually controlled infusion (MCI) of propofol with initial bolus 0.5 mg/kg and initial infusion rate 1.5 mg/kg/hr.
Study: 21863679
Drug: Effective-site target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective-site target controlled infusion (TCI) of propofol.
Study: 21863679
Drug: Manually controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually controlled infusion (MCI) of propofol.
Study: 17564405
Drug: Inactive oral
Normalized name: activated charcoal Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive oral device
Study: 7555937
Drug: Pull method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pull method with antibiotic prophylaxis (amoxycillin‐clavulanic acid 3 x 1.2 g i.v. over 24 hours); 37 patients
Study: 7555937
Drug: Pull method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pull method without antibiotic prophylaxis; 34 patients
Study: 7555937
Drug: Push method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Push method without antibiotic prophylaxis; 29 patients
Study: 7555937
Drug: Pull method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pull method with antibiotic prophylaxis; 37 patients
Study: 6803871
Drug: Propranolol (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (480 mg daily)
Study: 9260735
Drug: Nifedipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (60 mg daily)
Study: 6803871
Drug: Propranolol (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (480 mg daily) during cold pressor test
Study: 6803871
Drug: Propranolol (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (480 mg daily) during mental arithmetic test
Study: 19143915
Drug: Flexible-dose sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible-dose sildenafil (50 or 100 mg)
Study: 12187064
Drug: Sequential methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sequential methotrexate and 5-fluorouracil scheduling, epirubicin and cisplatin (MFAP regimen)
Study: 343250
Drug: Naloxone hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone hydrochloride (up to 10 mg)
Study: 30830540
Drug: Adjuvant dendritic
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant dendritic cell therapy
Study: 30830540
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment with curative intent
Study: 25715403
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment
Study: 22987089
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (2 g/d)
Study: 11407998
Drug: Sibutramine 15
Normalized name: sibutramine 15 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 15 mg
Study: 12131259
Drug: Placebo (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (200 g.d‐1 dextrose)
Study: 7588171
Drug: Clomipramine 50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 50-150 mg (mean daily dose 106 mg)
Study: 2254102
Drug: Classical radiation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical radiation therapy (IC)
Study: 29630433
Drug: Intensity-modulated radiotherapy
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity-modulated radiotherapy with concurrent systemic therapy
Study: 15860246
Drug: 2.5 mg/day
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/day glipizide GITS
Study: 11732515
Drug: Ketoprofen 25
Normalized name: ketoprofen 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 25 mg rectally with i.v. placebo
Study: 11732515
Drug: Ketoprofen 25
Normalized name: ketoprofen 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 25 mg i.v. with rectal placebo
Study: 1320919
Drug: Intravenous granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous granisetron 2 micrograms/kg
Study: 1320919
Drug: Intravenous granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous granisetron 3 mg single-dose regimen (equivalent to 40 micrograms/kg in a 75 kg person)
Study: 6468816
Drug: Propafenon (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenon (900 mg/day)
Study: 9833745
Drug: Mexiletine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (600 mg/day)
Study: 30895903
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone 200 mg nocte
Study: 25042759
Drug: Group Drug
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Drug Counseling (GDC), n=48
Study: 21162959
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (H and G)
Study: 15572657
Drug: CAA supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAA supplements (15 g of essential amino acids and 30 g of carbohydrate)
Study: 11736858
Drug: (+)-chlorpheniramine 2
Normalized name: chlorpheniramine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+)-chlorpheniramine 2 mg
Study: 2142968
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate and ethinylestradiol (2 mg cyproterone acetate + 0.035 mg ethinyl‐estradiol days 1‐21, +10 mg cyproterone acetate days 1‐15) (n = 15)
Study: 2142968
Drug: Dexamethasone (0.25‐0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.25‐0.5 mg daily at 10 pm) (n = 13)
Study: 25609246
Drug: Ganitumab 20
Normalized name: Ganitumab
DrugBank: Ganitumab (DB12205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganitumab 20 mg/kg
Study: 23710586
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation (CRT) with cisplatin 40 mg/m² weekly × 5
Study: 16818817
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy in NYHA class II
Study: 16818817
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy in NYHA class III
Study: 10760105
Drug: Nutritional parameters
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional parameters (dietary protein intake, energy intake, serum albumin, transferrin, percentage body fat, skinfold thickness, urine creatinine excretion)
Study: 12631397
Drug: No endocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No endocrine treatment
Study: 18555744
Drug: DHA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish oil (6 g/day)
Study: 15533485
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 2 g three times daily on the day of and the first day after the operation
Study: 11403540
Drug: H2-receptor antagonists
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonists (cimetidine or ranitidine) or proton pump inhibitors
Study: 9740281
Drug: Tetracycline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (500 mg qid in adults and 12.5 mg/kg qid in children) for 3 days
Study: 9740281
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg bid in adults and 7.5 mg/kg bid in children) for 3 days
Study: 2655906
Drug: Cisapride 5
Normalized name: cisapride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 5 mg three times daily for four weeks
Study: 19772445
Drug: AIR inhaled
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIR inhaled insulin
Study: 19772451
Drug: AIR inhaled
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIR inhaled insulin plus intensified insulin glargine (AIR + IG)
Study: 9211437
Drug: d-fenfluramine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-fenfluramine (30 mg p.o.)
Study: 30985644
Drug: Eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 50 mg
Study: 20219602
Drug: IAN block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAN block with 1.8 mL of Lidocaine 2% with 1:80,000 epinephrine
Study: 20219602
Drug: IAN block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAN block with 3.6 mL of Lidocaine 2% with 1:80,000 epinephrine
Study: 20219602
Drug: IAN block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAN block with 1.8 mL and buccal infiltration with 1.8 mL of Lidocaine 2% with 1:80,000 epinephrine
Study: 12425844
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia (1.8 ml of 2% lidocaine injected 15 minutes before treatment)
Study: 10805067
Drug: Problem-based pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-based pharmacotherapy training
Study: 10805067
Drug: Basic knowledge
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic knowledge about drugs
Study: 8678631
Drug: Hypothermic CPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermic CPB (rectal temperature, 27 degrees C to 28 degrees C)
Study: 8678631
Drug: Normothermic CPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermic CPB (rectal temperature, more than 35 degrees C)
Study: 1864299
Drug: Single-dose prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose prophylaxis
Study: 7060323
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg verapamil intravenously
Study: 7060323
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg verapamil orally
Study: 7060323
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg verapamil orally
Study: 7060323
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg verapamil orally
Study: 30409780
Drug: Aldosterone levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone levels in response to angiotensin-II infusion
Study: 25773888
Drug: PhyS-milk (1.57
Approvals — FDA: no, EMA: no, PMDA: no
Description: PhyS-milk (1.57 g PhyS in 250 ml/day)
Study: 25773888
Drug: ω3-milk (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω3-milk (375 mg ω3 in 250 ml/day)
Study: 21569373
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy following the CAPOX treatment scheme
Study: 8876706
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg finasteride
Study: 2189187
Drug: Salk killed
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salk killed virus vaccine
Study: 26908796
Drug: Artemether-Lumefantrine (A-L)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-Lumefantrine (A-L)
Study: 10402156
Drug: Spanish version
Normalized name: Spanish thyme oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI) after administration of sedatives (alcohol, triazolam, flunitrazepam)
Study: 10402156
Drug: Spanish version
Normalized name: Spanish thyme oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI) after administration of stimulants (cocaine)
Study: 10402156
Drug: Spanish version
Normalized name: Spanish thyme oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI) after administration of opioids (morphine, pentazocine, naloxone)
Study: 7001898
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment with hydrochlorothiazide, with possible addition of alphamethyldopa or propranolol if needed.
Study: 7001898
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no drug treatment).
Study: 7001898
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment group (with diastolic blood pressure >= 100 mm Hg before randomization).
Study: 31729126
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure lowering medications
Study: 21367545
Drug: 16 g
Normalized name: Maltsupex, 16 g/15 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g of ethanol daily (females)
Study: 21367545
Drug: 32 g
Normalized name: PEG-32 Glyceryl Laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 g of ethanol daily (males)
Study: 15023462
Drug: Fast formulation
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast formulation of starch acetate-diltiazem tablets
Study: 15023462
Drug: Slow formulation
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow formulation of starch acetate-diltiazem tablets
Study: 7638765
Drug: Continuous force
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous force of 50 cN (approximately 50 g)
Study: 7638765
Drug: Continuous force
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous force of 100 cN (approximately 100 g)
Study: 7638765
Drug: Continuous force
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous force of 200 cN (approximately 200 g)
Study: 2677862
Drug: Intravenous ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ampicillin plus oral erythromycin
Study: 16583374
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (ERT) with 0.2 mg/kg of alpha-galactosidase A (agalsidase-alfa) every 2 weeks for 6 months followed by 12 months of open-label ERT
Study: 10994682
Drug: Standard Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Day Treatment Program (DTP)
Study: 12868995
Drug: OKT3 induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKT3 induction therapy
Study: 6085189
Drug: Secretin plus
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Secretin plus Thr28Nle31CCK25‐33 (continuous 6-day intravenous infusion)
Study: 30409942
Drug: Xylitol chewing
Normalized name: xylitol Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol chewing gums, used thrice daily for 2 weeks
Study: 9240867
Drug: Zidovudine administration
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine administration to mothers during prenatal and intrapartum periods, and to neonates for 6 weeks
Study: 2600195
Drug: Diltiazem 30
Normalized name: diltiazem 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 30 mg
Study: 3286041
Drug: Diltiazem 30
Normalized name: diltiazem 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 30 mg plus Nifedipine 10 mg
Study: 3286041
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg with Diltiazem
Study: 11874389
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg meloxicam once
Study: 11874389
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ibuprofen three times daily
Study: 11874389
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg diclofenac SR once
Study: 8930782
Drug: Befloxatone 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befloxatone 5 mg
Study: 8904739
Drug: Befloxatone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befloxatone 10 mg
Study: 8904739
Drug: Befloxatone 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befloxatone 20 mg
Study: 1327933
Drug: Low-fiber wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fiber wheat bread (200-300 g/day)
Study: 3886305
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg alizapride/kg body weight
Study: 3886305
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg domperidone/kg
Study: 22954674
Drug: Rice containing
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice containing 6.51 g resistant starch daily